Theorem Clinical Research

R&D Trends

Ferring Pharmaceuticals acquires BioSET orthobiologic product candidates

Thursday, February 19, 2015 02:37 PM

Ferring Pharmaceuticals, based in Saint Prex, Switzerland, has acquired the assets of Maryland-based BioSurface Engineering Technologies (BioSET), including two phase III ready orthobiologic product candidates designed to improve bone repair. The initial indications for Amplex and Prefix to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively. Both products are based on a unique biomimetic peptide designed to enhance the body’s own natural mechanisms of bone repair.

More... »

Quest Diagnostics

Alzheimer's Research U.K. launches three Drug Discovery Institutes

Wednesday, February 18, 2015 11:57 AM

Alzheimer's Research U.K., a dedicated dementia research charity, has announced a $46.3 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of CambridgeOxford and University College London (UCL). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer's disease and other dementias.

More... »

Sanofi, Lead Pharma partner to develop treatments for autoimmune diseases

Wednesday, February 18, 2015 11:55 AM

Sanofi has entered into a research collaboration and license agreement with Dutch biotech Lead Pharma to discover, develop and commercialize small-molecule therapies directed against the nuclear hormone receptors called ROR gamma t to treat a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease, which are among the most common.

More... »

Angle, MD Anderson Cancer Center collaborate on colorectal cancer

Wednesday, February 18, 2015 11:49 AM

Angle, a specialist medtech company based in England, is collaborating with the MD Anderson Cancer Center to investigate the clinical use of Angle's Parsortix system as a companion diagnostic in colorectal cancer. The University of Texas MD Anderson Cancer Center is a center devoted exclusively to cancer patient care, research, education and prevention.

More... »

Dako, Ono Pharmaceutical to collaborate on diagnostic test Opdivo

Wednesday, February 18, 2015 11:45 AM

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

More... »

Janssen R&D launches three new research platforms

Friday, February 13, 2015 11:35 AM

Janssen R&D, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has launched three new research platforms focused on disease prevention, disease interception and the microbiome—areas of transformational medical innovation that are expected to change the healthcare landscape. The new teams will collaborate closely with Janssen’s five therapeutic areas as well as external partners, to underpin ongoing research and propel scientific knowledge.

More... »

Affinivax, PATH collaborate on pneumococcal disease vaccine candidate

Friday, February 13, 2015 11:30 AM

Affinivax, a Cambridge, Mass.-based biotechnology company dedicated to developing novel vaccines, has entered into a collaboration with PATH, a global health nonprofit organization, to advance the company’s lead vaccine candidate for Streptococcus pneumoniae (pneumococcus). The partnership includes funding from PATH to support product development, preclinical testing and manufacturing, with the goal to qualify and select a final development candidate to advance toward clinical testing.

More... »

UT Southwestern to establish Center for Heavy Ion Radiation Therapy

Thursday, February 12, 2015 01:07 PM

UT Southwestern Medical Center is leading a Texas consortium of researchers to establish the country's first National Center for Heavy Ion Radiation Therapy that could provide clinical care and research using heavy particles for innovative new cancer treatments.

More... »

Thiel Foundation's Breakout Labs selects three early-stage companies for funding

Thursday, February 12, 2015 01:05 PM

Breakout Labs, a seed-stage revolving fund operating out of the nonprofit Thiel Foundation in San Francisco, has announced three new companies have been selected for funding. These companies include Neumitra, Ion Dx, E3XBio.

More... »

Advaxis, Incyte collaborate on early stage cervical cancer immunotherapies

Thursday, February 12, 2015 01:04 PM

Advaxis, a Princeton, N.J.-based clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). Incyte is a pharmaceutical company based in Alapocas, Del.

More... »


March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs